UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 
 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 

Date of Report (Date of the earliest event reported)

July 25, 2018

 
 

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

 
 
 

Delaware

000-20852

16-1387013

(State of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

 2000 Technology Parkway, Newark, New York

14513

 (Address of principal executive offices)

(Zip Code)

 

(315) 332-7100

(Registrant’s telephone number, including area code)

 
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.   Emerging growth company  [ ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 


 

 

 

 

Item 5.07     Submission of Matters to a Vote of Security Holders.

 

 

On July 25, 2018, Ultralife Corporation (“the Company”) held its 2018 Annual Meeting of Shareholders (the “Annual Meeting”). Only shareholders of record at the close of business on May 29, 2018 (the “Record Date”) were entitled to vote at the Annual Meeting . As of the Record Date, there were 15,924,811 shares of common stock outstanding and entitled to vote, of which 15,505,737 (97.4%) were present in person or by proxy, representing a quorum. The results of shareholder voting on the proposals presented were as follows:

 

 

1.     The Company’s shareholders elected six Directors, all of whom constitute the Company’s entire Board of Directors, to serve for a term of one year and until their successors are duly elected and qualified. The number of shares that (i) voted for the election of each Director, (ii) withheld authority to vote for each Director, and (iii) were broker non-votes, are set forth in the table below.

 

 

Director

For

Withheld

Broker Non-Votes

       

Steven M. Anderson

11,558,776

401,359

3,545,602

Michael D. Popielec

11,567,419

392,716

3,545,602

Thomas L. Saeli

11,568,626

391,509

3,545,602

Robert W. Shaw II

11,558,775

401,360

3,545,602

Ranjit C. Singh

11,031,740

928,395

3,545,602

Bradford T. Whitmore

11,537,128

423,007

3,545,602

 

 

2.     The Company’s shareholders ratified the selection of the Company’s independent registered accounting firm as Freed Maxick CPA’s P.C. for 2018. The number of shares that (i) voted for the ratification of the accounting firm, (ii) voted against the ratification, and (iii) abstained from the vote are set forth in the table below.

 

For

Against

Abstain

     

15,452,501

14,962

38,274

 

 

3.      The Company’s shareholders did not approve a shareholder proposal entitled, “Special Shareholder Meeting Improvement”. The number of shares that (i) voted for the proposal, (ii) voted against the proposal, (iii) abstained from the vote, and (iv) were broker non-votes, are set forth in the table below.

 

For

Against

Abstain

Broker Non-Votes

       
3,184,184 8,735,201 40,750 3,545,602

                                              

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 27, 2018

 

ULTRALIFE Corporation

     
     
 

By:       

/s/ Philip A. Fain

   

Philip A. Fain

   

Chief Financial Officer and Treasurer